Immunicom, Inc.
PrivateLast Round
Grant
Jun 14, 2022
Total Funding Raised
$14.85M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Immunicom, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Grant round in June 2022.
Immunicom, Inc. is a medical technology company that has developed a subtractive immunotherapy platform, Immunopheresis®, designed to treat cancer and other diseases by filtering harmful elements from the blood.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunicom, Inc. Comparables
Compare Immunicom, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aethlon Medical, Inc. | 78% | |
| MediSieve | 77% | |
| ExThera Medical | 71% |
For institutional investors. Book with your work email.
Immunicom, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 14, 2022 | ||||
| Series B Extension | Sep 9, 2019 | ||||
| Series B | Jul 2, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunicom, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 82% MoM, reaching 3.3K.
- Jul 25, 2026
Monthly visitors increased 38% MoM, reaching 1.8K.
For institutional investors. Book with your work email.
Immunicom, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunicom, Inc.'s valuation, stock price, and market status.
Is Immunicom, Inc. a public or private company?
Immunicom, Inc. is a private company.
What is the current stock price of Immunicom, Inc.?
Immunicom, Inc. is a private company, so its shares have no public market price. Caplight tracks Immunicom, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunicom, Inc. worth (valuation)?
Valuation information for Immunicom, Inc. is not publicly available.
Can I buy Immunicom, Inc. stock?
Immunicom, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunicom, Inc.'s last funding round?
Immunicom, Inc.'s most recent funding round was Grant on June 14, 2022.
Who are the main investors in Immunicom, Inc.?
Key investors in Immunicom, Inc. include National Cancer Institute, NIH RADx.
Will Immunicom, Inc. IPO soon?
No public IPO plans have been announced for Immunicom, Inc..
How can I track Immunicom, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Immunicom, Inc.'s shares on secondary markets.